Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.99
NSPH's Cash to Debt is ranked lower than
66% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. NSPH: 0.99 )
Ranked among companies with meaningful Cash to Debt only.
NSPH' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 15.19 Max: No Debt
Current: 0.99
Equity to Asset 0.46
NSPH's Equity to Asset is ranked lower than
71% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NSPH: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
NSPH' s Equity to Asset Range Over the Past 10 Years
Min: -5.28  Med: 0.73 Max: 0.91
Current: 0.46
-5.28
0.91
F-Score: 4
Z-Score: -16.83
M-Score: -2.99
WACC vs ROIC
22.85%
-166.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -131.44
NSPH's Operating margin (%) is ranked lower than
70% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. NSPH: -131.44 )
Ranked among companies with meaningful Operating margin (%) only.
NSPH' s Operating margin (%) Range Over the Past 10 Years
Min: -2890.06  Med: -1446.03 Max: -131.44
Current: -131.44
-2890.06
-131.44
Net-margin (%) -145.18
NSPH's Net-margin (%) is ranked lower than
74% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.99 vs. NSPH: -145.18 )
Ranked among companies with meaningful Net-margin (%) only.
NSPH' s Net-margin (%) Range Over the Past 10 Years
Min: -4551.67  Med: -1465.84 Max: -145.17
Current: -145.18
-4551.67
-145.17
ROE (%) -209.48
NSPH's ROE (%) is ranked lower than
92% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.45 vs. NSPH: -209.48 )
Ranked among companies with meaningful ROE (%) only.
NSPH' s ROE (%) Range Over the Past 10 Years
Min: -2988.54  Med: -78.59 Max: -40.32
Current: -209.48
-2988.54
-40.32
ROA (%) -75.88
NSPH's ROA (%) is ranked lower than
81% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.96 vs. NSPH: -75.88 )
Ranked among companies with meaningful ROA (%) only.
NSPH' s ROA (%) Range Over the Past 10 Years
Min: -89.84  Med: -66.06 Max: -34.8
Current: -75.88
-89.84
-34.8
ROC (Joel Greenblatt) (%) -189.23
NSPH's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. NSPH: -189.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NSPH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -733.01  Med: -506.81 Max: -183.98
Current: -189.23
-733.01
-183.98
Revenue Growth (3Y)(%) 12.80
NSPH's Revenue Growth (3Y)(%) is ranked higher than
76% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. NSPH: 12.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NSPH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.9  Med: 2.80 Max: 49.9
Current: 12.8
-72.9
49.9
EBITDA Growth (3Y)(%) -33.20
NSPH's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. NSPH: -33.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NSPH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.20 Max: 34.7
Current: -33.2
0
34.7
EPS Growth (3Y)(%) -23.40
NSPH's EPS Growth (3Y)(%) is ranked lower than
76% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.60 vs. NSPH: -23.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NSPH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.8  Med: -23.40 Max: 48.1
Current: -23.4
-69.8
48.1
» NSPH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

NSPH Guru Trades in Q1 2015

John Keeley 26,000 sh (New)
Jim Simons 1,046,162 sh (+267.77%)
» More
Q2 2015

NSPH Guru Trades in Q2 2015

Jim Simons 117,103 sh (+123.87%)
John Keeley Sold Out
» More
Q3 2015

NSPH Guru Trades in Q3 2015

Jim Simons 196,003 sh (+67.38%)
» More
Q4 2015

NSPH Guru Trades in Q4 2015

Jim Simons 353,282 sh (+80.24%)
» More
» Details

Insider Trades

Latest Guru Trades with NSPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.63
NSPH's P/B is ranked higher than
96% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. NSPH: 0.63 )
Ranked among companies with meaningful P/B only.
NSPH' s P/B Range Over the Past 10 Years
Min: 0.48  Med: 2.11 Max: 7.33
Current: 0.63
0.48
7.33
P/S 0.24
NSPH's P/S is ranked higher than
96% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. NSPH: 0.24 )
Ranked among companies with meaningful P/S only.
NSPH' s P/S Range Over the Past 10 Years
Min: 0.19  Med: 24.99 Max: 137.11
Current: 0.24
0.19
137.11
Current Ratio 1.35
NSPH's Current Ratio is ranked lower than
80% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. NSPH: 1.35 )
Ranked among companies with meaningful Current Ratio only.
NSPH' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 8.17 Max: 12.58
Current: 1.35
0.63
12.58
Quick Ratio 1.08
NSPH's Quick Ratio is ranked lower than
79% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. NSPH: 1.08 )
Ranked among companies with meaningful Quick Ratio only.
NSPH' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 7.36 Max: 12.37
Current: 1.08
0.61
12.37
Days Inventory 255.64
NSPH's Days Inventory is ranked lower than
94% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. NSPH: 255.64 )
Ranked among companies with meaningful Days Inventory only.
NSPH' s Days Inventory Range Over the Past 10 Years
Min: 228.26  Med: 450.65 Max: 5940.08
Current: 255.64
228.26
5940.08
Days Sales Outstanding 73.89
NSPH's Days Sales Outstanding is ranked lower than
57% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.42 vs. NSPH: 73.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.43  Med: 88.42 Max: 124.07
Current: 73.89
14.43
124.07
Days Payable 52.28
NSPH's Days Payable is ranked lower than
52% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.01 vs. NSPH: 52.28 )
Ranked among companies with meaningful Days Payable only.
NSPH' s Days Payable Range Over the Past 10 Years
Min: 52.28  Med: 390.42 Max: 17661.29
Current: 52.28
52.28
17661.29

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.33
NSPH's Price/Net Current Asset Value is ranked higher than
86% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.07 vs. NSPH: 2.33 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NSPH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.61  Med: 2.57 Max: 4.75
Current: 2.33
1.61
4.75
Price/Tangible Book 0.69
NSPH's Price/Tangible Book is ranked higher than
94% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.31 vs. NSPH: 0.69 )
Ranked among companies with meaningful Price/Tangible Book only.
NSPH' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.55  Med: 2.36 Max: 4.28
Current: 0.69
0.55
4.28
Price/Median PS Value 0.01
NSPH's Price/Median PS Value is ranked higher than
99% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. NSPH: 0.01 )
Ranked among companies with meaningful Price/Median PS Value only.
NSPH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.82 Max: 3.08
Current: 0.01
0.01
3.08
Earnings Yield (Greenblatt) (%) -201.86
NSPH's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. NSPH: -201.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NSPH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -205.33  Med: 66.90 Max: 3708.9
Current: -201.86
-205.33
3708.9

More Statistics

Revenue(Mil) $21
EPS $ -6.13
Beta2.75
Short Percentage of Float1.43%
52-Week Range $0.48 - 4.87
Shares Outstanding(Mil)12.27

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 27 36
EPS($) -1.28 -0.49
EPS without NRI($) -1.28 -0.49

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:OXIS, NAS:GBSN, NAS:IDXG, TSX:GEN, XCNQ:CHX » details
Traded in other countries:3NSN.Germany,
Nanosphere, Inc., was incorporated in 1999 in Delaware. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
» More Articles for NSPH

Headlines

Articles On GuruFocus.com
Wednesday’s Pre-Market Insights: PBR, SDRL, WDAY, EMC, BLUE May 27 2015 
NANOSPHERE, INC. Reports Operating Results (10-Q) Aug 05 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 06 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) Nov 05 2009 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
NANOSPHERE INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 22 2016
Coverage initiated on Nanosphere by Rodman & Renshaw Mar 08 2016
Nanosphere’s Verigene BC-GP Decreases Patient Length of Stay Mar 03 2016
NANOSPHERE INC Financials Mar 01 2016
Nanosphere, Inc. Earnings Analysis: 2015 By the Numbers Mar 01 2016
Edited Transcript of NSPH earnings conference call or presentation 24-Feb-16 10:00pm GMT Feb 25 2016
Nanosphere Inc Earnings Call scheduled for 5:00 pm ET today Feb 24 2016
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 24 2016
Nanosphere Announces Fourth Quarter and Full Year 2015 Results, 2016 Guidance and Next Generation... Feb 24 2016
Q4 2015 Nanosphere Inc Earnings Release - After Market Close Feb 24 2016
Nanosphere to Announce Fourth Quarter Financial Results and Host Investor Call on Wednesday,... Feb 11 2016
NANOSPHERE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Jan 29 2016
4 Stocks Under $10 Making Big Moves Higher Jan 08 2016
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition Jan 06 2016
Nanosphere Announces Record Preliminary Q4 and Full Year 2015 Results Jan 06 2016
Nanosphere, Inc. Announces Completion of $10 Million Registered Public Offering Dec 22 2015
NANOSPHERE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2015
NANOSPHERE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to... Dec 18 2015
Nanosphere, Inc. Announces $10 Million Registered Public Offering Dec 17 2015
NANOSPHERE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK